Beryl Drugs Limited convened an Extra-Ordinary General Meeting (EGM) on Monday, May 11, 2026, at Kanchan Palace, Community Hall, Nipania Ring Road, Indore - 452001. The meeting commenced at 11:00 A.M. and concluded at 11:30 A.M., with 46 members in attendance against a minimum quorum requirement of 30 members. The total number of members as on the cut-off date of 4th May, 2026 was 7,360. Members transacted key business with requisite majority, resulting in the approval of three significant resolutions pertaining to board composition and a material related party transaction.

Key Resolutions Passed at the EGM

The following table summarises the resolutions approved by shareholders at the EGM:

All three resolutions were passed as Ordinary Resolutions through a combination of Remote E-voting and Poll. The company appointed CS Dipika Kataria, Practicing Company Secretary (FCS 8078, CP 9526), as scrutinizer to oversee the remote e-voting and venue voting in a fair and transparent manner. The consolidated results of the e-voting and poll were declared within 48 hours and displayed on BSE Limited.

Regularisation of Mr. Shailendra Pathak as Whole-Time Director

The shareholders approved the regularisation of the appointment of Mr. Shailendra Pathak (DIN: 11169772) as Whole-Time Director of Beryl Drugs Limited. Mr. Pathak was originally appointed as an Additional Director designated as Whole-Time Director by the Board of Directors in their meeting held on 3rd January 2026, pursuant to Section 161(1) of the Companies Act, 2013. His appointment was valid up to the conclusion of the next general meeting, subject to shareholder approval. The EGM formally regularised and approved his appointment for a period of 5 (Five) years with effect from the conclusion of the EGM, liable to retire by rotation.

The key details of Mr. Pathak's appointment, as disclosed pursuant to SEBI Circular bearing reference no. CIR/CFD/CMD/4/2015 dated September 09, 2015, are as follows:

Director Profile and Remuneration

Mr. Shailendra Pathak is an Engineer by qualification with more than 35 years of experience in the pharmaceutical industry, specialising in IV fluids and Oral Solid Doses (OSD) manufacturing. He has experience in setting up state-of-the-art pharmaceutical plants through to commercial production and marketing. The terms and conditions of his appointment, including remuneration, are summarised below:

Appointment of Mrs. Neha Sarda as Independent Director

The shareholders also approved the regularisation of the appointment of Mrs. Neha Sarda (DIN: 08456141) as an Independent Director of Beryl Drugs Limited. Mrs. Sarda was originally appointed as an Additional Director (Non-Executive-Independent) by the Board of Directors in their meeting held on 3rd January 2026, pursuant to Section 161(1) of the Companies Act, 2013. Her appointment was valid up to the conclusion of the next general meeting, subject to member approval. The EGM formally regularised her appointment for a term of 5 consecutive years with effect from 11th May, 2026, not liable to retire by rotation.

The company has confirmed that Mrs. Sarda meets the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details of her appointment are as follows:

Material Related Party Transaction with Aminova Infusions Pvt. Ltd.

In addition to the director appointments, the EGM members approved a material related party transaction with M/s. Aminova Infusions Pvt. Ltd., pursuant to Regulation 30 read with Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction pertains to the distribution of Beryl Drugs' products in markets such as Maharashtra and Gujarat, as well as exports to other countries. The relationship arises from Mr. Shailendra Pathak — the newly regularised Whole-Time Director — being the promoter and majority shareholder of Aminova, thereby classifying Aminova as a related party under Section 2(76) of the Companies Act, 2013.

The Audit Committee reviewed and approved the transaction at its meeting held on 3rd January 2026, subject to member approval, confirming that it is on an arm's length basis and in the ordinary course of business. The company noted that it sells products to other vendors on the same terms and conditions, reinforcing the arm's length nature of the arrangement. The full details of the approved transaction are as follows:

Material Terms of the Transaction

The key material terms governing the transaction between Beryl Drugs and Aminova Infusions are as follows:

• Prices to be based on market rates and on an ex-factory basis
• Payment as per market terms
• The company shall not be responsible for breakage once goods are handed over to Aminova, but will replace products in case of leakage on receipt of empty bottles with seal intact
• Supplies subject to availability of stock
• Rates subject to revision without prior intimation
• Taxes to be charged extra at applicable rates
• Transactions subject to Indore jurisdiction
• In the event of any dispute, the matter shall be referred to Sole Arbitrator Mr. Ritesh Jain, with arbitration conducted at Indore under the Arbitration and Conciliation Act, 1996

Justification for the Related Party Transaction

The company stated that Mr. Shailendra Pathak is a veteran in the pharmaceutical field with exposure to other markets including foreign markets. The transaction is expected to help Beryl Drugs access a larger market segment, which may significantly increase the company's turnover and profits. The promoters of the company have known Mr. Pathak for 10–15 years, and the RPT is intended to utilise his full knowledge, expertise, and market exposure for the benefit of the company.

Meeting Details and Communication

The EGM was chaired by Mr. Sudhir Sethi, Chairman of the Board, and the proceedings were confirmed to have been called, convened, held, and conducted as per the provisions of the Companies Act, 2013, the applicable rules, and secretarial standards. The outcome of the EGM, including the approval of director appointments and the material related party transaction, was communicated to BSE Limited by Sanjay Sethi, Managing Director (DIN: 00090277), on behalf of Beryl Drugs Limited, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is registered at Ground Floor, 133, Kanchan Bagh, Indore - 452001, Madhya Pradesh, with CIN: L02423MP1993PLC007840.

Beryl Drugs Limited has submitted a regulatory declaration to BSE Limited confirming its status regarding Large Entity classification under Securities and Exchange Board of India (SEBI) regulations. The pharmaceutical company made this disclosure as part of its ongoing compliance obligations with stock exchange requirements.

Regulatory Compliance Declaration

The company filed its declaration on April 6, 2026, addressing the requirements outlined in SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. This circular, read in conjunction with BSE Circular No. LIST/COMP/05/2019-20 dated April 11, 2019, mandates listed companies to declare their status regarding Large Entity or Large Corporate classification.

Company Status Confirmation

Beryl Drugs Limited confirmed that it does not qualify as a Large Entity or Large Corporate as defined under clause 2.2 of the SEBI circular as on March 31, 2026. This classification has implications for various regulatory requirements and compliance obligations that apply differently to large entities versus smaller companies.

Management Authorization

The declaration was signed by Sanjay Sethi, Managing Director of Beryl Drugs Limited, who holds Director Identification Number (DIN) 00090277. The document was submitted to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, as part of the company's regulatory filing obligations.

Company Information

Beryl Drugs Limited operates from its registered office located at Ground Floor, 133, Kanchan Bagh, Indore - 452001, Madhya Pradesh. The company maintains its corporate identification number as L02423MP1993PLC007840, reflecting its incorporation status and business classification within the pharmaceutical sector.